Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
BMC Prim Care ; 25(1): 150, 2024 May 04.
Article in English | MEDLINE | ID: mdl-38704552

ABSTRACT

BACKGROUND: The aim of our study is to analyse the trends in the diagnosis of sexually transmitted infections (STIs) during the COVID-19 pandemic. METHODS: We conducted an observational retrospective population-based study using data from primary care electronic health records spanning from January 2016 to December 2022 (involving 5.1 million people older than 14 years). We described the daily number of new STI diagnoses from 2016 to 2022; as well as the monthly accumulation of new STI diagnoses for each year. We compared the monthly averages of new diagnoses in 2019, 2020, 2021 and 2022 using the T-test. Finally, we performed a segmented regression analysis of the daily number of STI diagnoses. RESULTS: We analysed 200,676 new STI diagnoses. The number of diagnoses abruptly decreased coinciding with the lockdown. Overall in 2020, we observed a reduction of 15%, with higher reductions for specific STIs such as gonorrhoea (-21%), chlamydia (-24%), and HIV (-31%) compared to 2019. Following this drastic drop, which was temporarily associated with the lockdown, we observed a rapid rebound. In 2021, the number of STI diagnoses was similar to that of 2019. Notably, we found a considerable increase in 2022, particularly for non-specific STI, which lack laboratory confirmation (67% increase). HIV was the only STI with a reduction of up to -38% in diagnoses at the end of 2022 compared to 2019. CONCLUSIONS: After a significant reduction in 2020, the number of STIs recorded in primary care rapidly rebounded, and the current trend is similar to that of 2019, except for HIV. These findings underscore the dynamic impact of the COVID-19 pandemic on STI diagnoses and highlight the importance of ongoing monitoring and public health interventions in the post-pandemic period.


Subject(s)
COVID-19 , Electronic Health Records , Primary Health Care , Sexually Transmitted Diseases , Humans , COVID-19/epidemiology , COVID-19/prevention & control , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/diagnosis , Primary Health Care/statistics & numerical data , Retrospective Studies , Spain/epidemiology , Female , Male , Adult , SARS-CoV-2 , Adolescent , Middle Aged , Pandemics , Young Adult
2.
J Antimicrob Chemother ; 78(4): 975-982, 2023 04 03.
Article in English | MEDLINE | ID: mdl-36760088

ABSTRACT

BACKGROUND: Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. OBJECTIVES: To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. RESULTS: From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. CONCLUSIONS: We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens.


Subject(s)
Dysentery, Bacillary , Sexual and Gender Minorities , Shigella , Male , Humans , Shigella flexneri , Shigella sonnei , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Dysentery, Bacillary/epidemiology , Dysentery, Bacillary/drug therapy , Homosexuality, Male , Drug Resistance, Bacterial , Microbial Sensitivity Tests , Disease Outbreaks
3.
HIV Med ; 23(8): 868-879, 2022 09.
Article in English | MEDLINE | ID: mdl-35285143

ABSTRACT

OBJECTIVE: The aim of this study was to assess the efficacy of an electronic reminder in primary healthcare in patients diagnosed with an indicator condition (IC) to improve HIV screening. METHODS: We developed a prospective interventional study in 51 primary healthcare centres in Barcelona randomly assigned into one of two study groups: control and alert. Between June 2018 and May 2019, an electronic reminder appeared in the electronic medical record each time a diagnosis of an IC in patients aged 16-65 years was registered in the alert group. We assessed HIV testing rates within 4 months following the diagnosis of an IC. RESULTS: In all, 13 000 patients were diagnosed with at least one IC. HIV testing was more likely in the alert group than in the control group. The electronic reminder multiplied the odds of being tested in men by 1.26 [95% confidence interval (CI): 1.04-1.52, p = 0.019], by 1.77 (95% CI: 1.33-2.38, p < 0.001) among patients aged < 50 years , and by 1.51 (95% CI: 1.20-1.92, p < 0.001) in diagnoses of IC other than a sexually transmitted infection (STI) or an AIDS-defining illness. Five (0.08%) cases of HIV were detected in the control group and 10 (0.17%) in the alert group. CONCLUSIONS: Implementing an electronic reminder had a positive impact on HIV screening rates in patients diagnosed with an IC. The alert was more effective among older patients, those living in less socioeconomically deprived neighbourhoods, and those with an IC other than an STI or an AIDS-defining illness.


Subject(s)
Acquired Immunodeficiency Syndrome , HIV Infections , Sexually Transmitted Diseases , Adolescent , Adult , Aged , Electronics , Female , HIV Infections/diagnosis , HIV Infections/epidemiology , HIV Infections/prevention & control , HIV Testing , Humans , Male , Mass Screening , Middle Aged , Primary Health Care , Prospective Studies , Spain/epidemiology , Young Adult
4.
Int J Antimicrob Agents ; 58(3): 106378, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34157402

ABSTRACT

BACKGROUND: In high-income countries, shigellosis is mainly found in travellers to high-risk regions or in men who have sex with men (MSM). This study investigated the genomic characteristics and the features of antimicrobial resistance of MSM-associated Shigella flexneri and Shigella sonnei circulating in Barcelona, Spain, elucidating their connectivity with contemporaneous Shigella spp. from other countries. METHODS: Antimicrobial susceptibility, whole-genome sequencing, genomic characterization and phylogenetic analysis were performed in MSM-associated Shigella spp. recovered from 2015 to 2019. Reference genomes of MSM-associated Shigella spp. were included for contextualization and to determine their connection with international outbreaks. RESULTS: In total, 44 S. flexneri and 26 S. sonnei were identified among MSM. Overall, 80% showed resistance to azithromycin, 65.7% showed resistance to trimethoprim-sulphamethoxazole and 32.8% showed resistance to ciprofloxacin; 27.1% were resistant to all three antimicrobials. mphA and/or ermB, and qnrS and mutations in the quinolone resistance determining regions were found in the azithromycin- and ciprofloxacin-resistant isolates, respectively. Additionally, two isolates carried blaCTX-M-27. Single-nucleotide-polymorphism-based analysis revealed that the isolates were organized into different lineages, most of which were closely related to dominant MSM-associated lineages described previously in the UK and Australia. CONCLUSIONS: This study investigated the circulation of lineages of S. flexneri and S. sonnei among MSM in Spain that were mainly resistant to first-/second-line oral treatments, and closely related to dominant MSM-associated lineages described previously in the UK and Australia. These data reinforce the urgent need for the implementation of public health measures focusing on the early detection and prevention of transmission of this emerging pathogen, which is contributing to the antimicrobial resistance crisis in sexually transmitted infections.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Ciprofloxacin/therapeutic use , Drug Resistance, Multiple, Bacterial/genetics , Dysentery, Bacillary/drug therapy , Sexually Transmitted Diseases/drug therapy , Shigella/drug effects , Adult , Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Ciprofloxacin/pharmacology , Disease Susceptibility , Genetic Variation , Genome , Geography , Homosexuality, Male/statistics & numerical data , Humans , Male , Microbial Sensitivity Tests , Shigella/genetics , Spain , Whole Genome Sequencing
5.
Euro Surveill ; 25(42)2020 10.
Article in English | MEDLINE | ID: mdl-33094716

ABSTRACT

IntroductionIncreasing rates of antimicrobial resistance in Neisseria gonorrhoeae cause problems for treating gonorrhoea.AimThis observational study aimed to describe isolates from all patients found infected with N. gonorrhoeae, in Barcelona, Spain, between 2013 and 2017, and with available antimicrobial susceptibility data.MethodsMinimum inhibitory concentrations (MICs) of penicillin (PEN), cefixime (CFM), ceftriaxone (CRO), azithromycin (AZM), ciprofloxacin (CIP), spectinomycin (SPT), fosfomycin (FOF) and gentamicin (GEN) were determined by E-test. Susceptibility was assessed using clinical breakpoints from the European Committee on Antimicrobial Susceptibility Testing. Time trends for PEN, CFM, AZM and CIP were investigated using logistic regression.ResultsOf 1,979 patients with infection (2,036 isolates), 1,888 (95.4%) were men. Patient median age was 32 years. The proportions of isolates resistant to extended-spectrum cephalosporins were low, with 0.3% (5/1,982) resistant to CRO and 4.9% (98/1,985) to CFM. AZM resistance prevalence was 2.7% (52/1,981), including 16 isolates detected in 2016 and 2017, with high-level resistance. For CIP, 51.3% (1,018/1,986) of isolates were resistant, and for PEN, 20.1% (399/1,985). All isolates were susceptible to SPT. MIC50 and MIC90 values of GEN were 4 and 6 mg/L and of FOF 12 and 24 mg/L, respectively. Between 2013 and 2017, PEN and CFM resistance rates each decreased from 28.1% (92/327) to 12.2% (70/572) and from 8.3% (27/327) to 4.4% (25/572) (p ≤ 0.0073). In contrast, AZM resistance prevalence appeared to increase from 1.5% in 2014 (5/340) to 3.0% (17/572) in 2017. No trend was identified for CIP.ConclusionAntimicrobial susceptibility surveillance is important to timely detect new phenotypes and trends.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Gonorrhea/drug therapy , Gonorrhea/microbiology , Neisseria gonorrhoeae/drug effects , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Azithromycin/pharmacology , Cefixime/pharmacology , Ceftriaxone/pharmacology , Cephalosporins/pharmacology , Ciprofloxacin/pharmacology , Female , Gonorrhea/diagnosis , Gonorrhea/epidemiology , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Neisseria gonorrhoeae/isolation & purification , Penicillins/pharmacology , Spain/epidemiology , Spectinomycin/pharmacology , Tetracycline/pharmacology
6.
Gac. sanit. (Barc., Ed. impr.) ; 23(4): 348-350, jul.-ago. 2009. tab
Article in Spanish | IBECS | ID: ibc-72778

ABSTRACT

ObjetivoDescribir la capacidad y organización de los laboratorios de Cataluña (España) para el diagnóstico de infecciones de transmisión sexual. Para ello, entre noviembre de 2005 y marzo de 2006 se realizó un estudio transversal incluyendo 140 laboratorios.Resultados98 realizan alguna prueba diagnóstica, 45 reciben más de 50 muestras vaginales al mes, 42 diagnostican Chlamydia trachomatis, pero solo 6 mediante amplificación de ácidos nucleicos. Ninguno diagnostica el linfogranuloma venéreo. 80 detectan la Neisseria gonorrhoeae (n 1/4 80), 76 de ellos mediante cultivo y 63 analizan su sensibilidad antimicrobiana. En total 23, 22, 22 y 14 laboratorios reciben más de 500 peticiones al mes, respectivamente de hepatitis B, hepatitis C, VIH y sífilis. 84 disponen de pruebas no treponémicas parala sífilis y 51 disponen de pruebas treponémicas.ConclusionesLa actividad de los laboratorios cubre prácticamente todo el espectro patológico, pero es necesario introducir nuevas técnicas y mejorar la eficiencia de los circuitos de muestras(AU)


ObjectiveWith the aim of describing both the capacity and organization of the laboratories in Catalonia to diagnose sexually transmitted infections, a cross-sectional study was performed between November 2005 and March 2006, which included 140 laboratories.ResultsNinety-eight laboratories performed some STI tests, 45 received more than 50 vaginal swabs per month, 42 diagnosed Chlamydia trachomatis, but only six used polymerase chain reaction techniques. None diagnosed venereal lymphogranuloma. Eighty were able to detect Neisseria gonorrhoeae, 76 by means of culture and 63 analyzed its antibiotic resistance. A total of 23, 22, 22 and 14 laboratories received more than 500 blood samples for hepatitis B, hepatitis C, HIV and syphilis, respectively. Non-treponemic and treponemic tests were available in 84 and 52 laboratories, respectively.ConclusionsIn Catalonia, most STIs can be diagnosed but new technologies need to be introduced. Moreover, the efficiency of biological sample circuits should be improved(AU)


Subject(s)
Humans , Sexually Transmitted Diseases/diagnosis , Laboratories/statistics & numerical data , Clinical Laboratory Techniques/trends , Sexually Transmitted Diseases/epidemiology , Vaginal Smears/methods , Neisseria gonorrhoeae/isolation & purification , Chlamydia trachomatis/isolation & purification
7.
Gac Sanit ; 23(4): 348-50, 2009.
Article in Spanish | MEDLINE | ID: mdl-19596496

ABSTRACT

OBJECTIVE: With the aim of describing both the capacity and organization of the laboratories in Catalonia to diagnose sexually transmitted infections, a cross-sectional study was performed between November 2005 and March 2006, which included 140 laboratories. RESULTS: Ninety-eight laboratories performed some STI tests, 45 received more than 50 vaginal swabs per month, 42 diagnosed Chlamydia trachomatis, but only six used polymerase chain reaction techniques. None diagnosed venereal lymphogranuloma. Eighty were able to detect Neisseria gonorrhoeae, 76 by means of culture and 63 analyzed its antibiotic resistance. A total of 23, 22, 22 and 14 laboratories received more than 500 blood samples for hepatitis B, hepatitis C, HIV and syphilis, respectively. Non-treponemic and treponemic tests were available in 84 and 52 laboratories, respectively. CONCLUSIONS: In Catalonia, most STIs can be diagnosed but new technologies need to be introduced. Moreover, the efficiency of biological sample circuits should be improved.


Subject(s)
Diagnostic Tests, Routine/statistics & numerical data , Health Resources/statistics & numerical data , Laboratories/statistics & numerical data , Sexually Transmitted Diseases/diagnosis , Cross-Sectional Studies , Disease Notification/legislation & jurisprudence , Female , Health Services Needs and Demand , Humans , Laboratories/organization & administration , Lymphogranuloma Venereum/diagnosis , Lymphogranuloma Venereum/epidemiology , Male , Polymerase Chain Reaction/statistics & numerical data , Sexually Transmitted Diseases/epidemiology , Spain/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...